ABG logo

Cencora BST:ABG Stock Report

Last Price

€244.50

Market Cap

€47.4b

7D

9.3%

1Y

10.7%

Updated

06 Feb, 2025

Data

Company Financials +

Cencora, Inc.

BST:ABG Stock Report

Market Cap: €47.4b

ABG Stock Overview

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. More details

ABG fundamental analysis
Snowflake Score
Valuation2/6
Future Growth3/6
Past Performance1/6
Financial Health2/6
Dividends3/6

Rewards

Trading at 63.7% below our estimate of its fair value

Earnings are forecast to grow 15.38% per year

Risk Analysis

Debt is not well covered by operating cash flow

High level of non-cash earnings

Shares are highly illiquid

Significant insider selling over the past 3 months

+ 1 more risk

My Notes

Capture your thoughts, links and company narrative

Cencora, Inc. Competitors

Siemens Healthineers

XTRA:SHL

€60.0b

Fresenius Medical Care

XTRA:FME

€13.8b

Medios

XTRA:ILM1

€309.7m

McKesson

NYSE:MCK

US$76.6b

Price History & Performance

Summary of share price highs, lows and changes for Cencora
Historical stock prices
Current Share PriceUS$244.50
52 Week HighUS$246.05
52 Week LowUS$199.32
Beta0.49
1 Month Change9.30%
3 Month Changen/a
1 Year Change10.66%
3 Year Changen/a
5 Year Changen/a
Change since IPO68.23%

Recent News & Updates

Recent updates

Shareholder Returns

ABGDE HealthcareDE Market
7D9.3%-0.6%-0.2%
1Y10.7%37.3%13.7%

Return vs Industry: ABG underperformed the German Healthcare industry which returned 37.3% over the past year.

Return vs Market: ABG underperformed the German Market which returned 13.7% over the past year.

Price Volatility

Is ABG's price volatile compared to industry and market?
ABG volatility
ABG Average Weekly Movementn/a
Healthcare Industry Average Movement4.8%
Market Average Movement4.8%
10% most volatile stocks in DE Market11.1%
10% least volatile stocks in DE Market2.4%

Stable Share Price: ABG's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine ABG's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
187146,000Bob Mauchwww.cencora.com

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company’s U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.

Cencora, Inc. Fundamentals Summary

How do Cencora's earnings and revenue compare to its market cap?
ABG fundamental statistics
Market cap€47.40b
Earnings (TTM)€1.35b
Revenue (TTM)€292.61b

35.2x

P/E Ratio

0.2x

P/S Ratio

Is ABG overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ABG income statement (TTM)
RevenueUS$303.19b
Cost of RevenueUS$293.30b
Gross ProfitUS$9.90b
Other ExpensesUS$8.50b
EarningsUS$1.40b

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)7.20
Gross Margin3.26%
Net Profit Margin0.46%
Debt/Equity Ratio2,251.6%

How did ABG perform over the long term?

See historical performance and comparison

Dividends

0.9%

Current Dividend Yield

29%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/06 17:19
End of Day Share Price 2025/01/31 00:00
Earnings2024/12/31
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cencora, Inc. is covered by 39 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Gregory BolanAvondale Partners
Eric ColdwellBaird